Regeneron Pharmaceuticals Inc (REGN) Rating Reiterated by Canaccord Genuity

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)‘s stock had its “hold” rating restated by equities research analysts at Canaccord Genuity in a report issued on Friday. They currently have a $450.00 price objective on the biopharmaceutical company’s stock. Canaccord Genuity’s target price suggests a potential upside of 19.79% from the stock’s current price.

REGN has been the subject of a number of other research reports. BTIG Research reaffirmed a “neutral” rating on shares of Regeneron Pharmaceuticals in a report on Thursday, November 17th. Robert W. Baird reiterated a “neutral” rating and issued a $369.00 price objective (down previously from $379.00) on shares of Regeneron Pharmaceuticals in a research note on Sunday, January 8th. Morgan Stanley set a $370.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Monday, January 9th. Credit Suisse Group reiterated a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday. Finally, Piper Jaffray Companies set a $447.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, October 13th. Twelve analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $447.20.

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 375.66 on Friday. The stock’s 50 day moving average is $363.00 and its 200 day moving average is $385.93. The stock has a market capitalization of $39.49 billion, a price-to-earnings ratio of 48.79 and a beta of 1.44. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $452.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.01. The business earned $1.23 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a net margin of 18.10% and a return on equity of 22.51%. The business’s quarterly revenue was up 11.7% on a year-over-year basis. During the same quarter last year, the company posted $2.83 earnings per share. Equities analysts predict that Regeneron Pharmaceuticals will post $13.25 earnings per share for the current fiscal year.

This piece of content was first reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece of content on another site, it was illegally copied and republished in violation of US and international copyright and trademark laws. The legal version of this piece of content can be viewed at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-canaccord-genuity/1659586.html.

In other Regeneron Pharmaceuticals news, major shareholder Sanofi acquired 87,298 shares of the company’s stock in a transaction that occurred on Wednesday, January 11th. The stock was purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Charles A. Baker sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, December 12th. The shares were sold at an average price of $392.02, for a total transaction of $1,176,060.00. Following the completion of the transaction, the director now owns 12,000 shares of the company’s stock, valued at approximately $4,704,240. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc boosted its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 80 shares during the period. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the period. NEXT Financial Group Inc boosted its position in Regeneron Pharmaceuticals by 46.9% in the third quarter. NEXT Financial Group Inc now owns 360 shares of the biopharmaceutical company’s stock valued at $145,000 after buying an additional 115 shares during the period. Live Your Vision LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter valued at approximately $157,000. Finally, Global X Management Co. LLC boosted its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the period. Hedge funds and other institutional investors own 68.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.

5 Day Chart for NASDAQ:REGN

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-canaccord-genuity/1659586.html

Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *